EUVIMEDEUVIMED entdecken
Crossref

Overcoming contraindications in liver biopsy: n-butyl cyanoacrylate tract embolization for high-risk cases

Muhammet Kürşat Şimşek, Batuhan Kirişci, Tolga Zeydanlı, Özgür Özen, Fatih Boyvat

Developments and Experiments in Health and Medicine · 29.04.2026 · 40 (2) · 200-208

DOI: 10.18614/dehm.1768786 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Developments and Experiments in Health and Medicine, online erschienen am 29.04.2026. Verfasst von Muhammet Kürşat Şimşek und 4 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Liver biopsy is a well-established diagnostic method for assessing liver pathology. Percutaneous biopsy remains widely used but carries a risk of bleeding, particularly in patients with coagulopathy or other contraindications. This study evaluates the effectiveness of using N-butyl cyanoacrylate (NBCA) for tract embolization following percutaneous liver biopsy to reduce bleeding risk in high-risk patients.

Methods

We retrospectively analyzed 50 patients who underwent ultrasound-guided liver biopsy with NBCA embolization between 2020 and 2024. Indications for biopsy included ascites, coagulopathy, anticoagulant use, and hypervascular masses. The primary outcomes assessed were diagnostic success and complication rates, particularly bleeding.

Results

Patient ages ranged from 3 to 90 years, with a mean age of 53 (standard deviation: 24.28) years, and 54% were male. All procedures achieved sufficient tissue for diagnosis, with a 100% success rate, and no major complications or bleeding events were reported.

Conclusion

Our findings support the safety and effectiveness of NBCA tract embolization as an adjunct to percutaneous liver biopsy, enabling safer diagnostic access for patients with contraindications. Further studies are encouraged to validate these findings and optimize protocol standardization.

Zitieren

APA

Şimşek, M. K., Kirişci, B., Zeydanlı, T., Özen, Ö., & Boyvat, F. (2026). Overcoming contraindications in liver biopsy: n-butyl cyanoacrylate tract embolization for high-risk cases. Developments and Experiments in Health and Medicine, 40(2), 200-208. https://doi.org/10.18614/dehm.1768786

Vancouver

Şimşek MK, Kirişci B, Zeydanlı T, Özen Ö, Boyvat F. Overcoming contraindications in liver biopsy: n-butyl cyanoacrylate tract embolization for high-risk cases. Developments and Experiments in Health and Medicine. 2026;40(2):200-208. doi:10.18614/dehm.1768786

BibTeX
@article{imek2026,
  author = {Şimşek, Muhammet Kürşat and Kirişci, Batuhan and Zeydanlı, Tolga and Özen, Özgür and Boyvat, Fatih},
  title = {Overcoming contraindications in liver biopsy: n-butyl cyanoacrylate tract embolization for high-risk cases},
  journal = {Developments and Experiments in Health and Medicine},
  year = {2026},
  volume = {40},
  number = {2},
  pages = {200--208},
  doi = {10.18614/dehm.1768786}
}
Kostenlos starten →